As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

The Abrysvo vaccine protects infants – who are highly susceptible to respiratory syncytial virus (RSV) – against lower ...

The Food and Drug Administration (FDA) approved the nation’s first RSV vaccine, GSK’s Arexvy, on May 3 ... cited the following among their reasoning: Concerns about side effects from the vaccine: 45% ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...

Clarivate Plc  a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watchtm report, a trusted guide to the therapies poised to redefine ...

The FDA on Tuesday revealed that it has detected severe side effects in two of Moderna’s experimental mRNA-based respiratory syncytial vaccine candidates ... the FDA’s first approval in May 2023 for ...

compared to the current adjuvanted RSV vaccine, a lower incidence of side effects.” Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

“When we compared the antibody responses between those study participants who received Arexvy with those who got Abrysvo, we found that the group receiving the adjuvanted vaccine tended to have ...